0:00 / 0:00
Treatments for pyoderma gangrenosum: the STOP GAP RCT
The BMJ
45K subscribers • 26 videos on Rounds • Health institution
- Published by The BMJ, one of the health institutions Rounds lists. Nobody has recommended it in the communities yet, so it ranks below community picks.
- The description links 1 paper.
- May be out of date. Uploaded 11 years ago, in an area where guidance changes.
Aimed at clinicians, students or researchers. Education, not medical advice.
16K views11 years ago
Clinical medicineEvidence and public healthHow drugs workThe immune systemClinical skills and exams
An overview of a randomized controlled trial comparing the effectiveness of ciclosporin and prednisolone for treating pyoderma gangrenosum.
Pyoderma gangrenosum is a rare inflammatory disorder that causes progressive necrotising ulceration. A retrospective cohort study of UK cases reported an age and sex adjusted incidence of 0.63 per 100,000 person years. Currently there are no national or international guidelines covering the management of pyoderma gangrenosum. Patient information issued by the British Association of Dermatologists describes topical and systemic treatment options, as well as lesser used options such as intravenous steroids or biologics. The most commonly prescribed topical treatments for pyoderma gangrenosum are potent steroid preparations and calcineurin inhibitors, and commonly prescribed systemic treatments include steroids and immunosuppressants. In the STOP GAP study, the researchers set out to determine whether ciclosporin is superior to prednisolone for the treatment of pyoderma gangrenosum. Read the full research: bmj.com/content/350/bmj.h2958Why it's here
From a health institutionThe BMJ is on Rounds' list of health institutions, and this upload is one of its most-watched lectures or explainers. Nobody has recommended it in the communities yet, so it ranks below community picks.